<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Biol</journal-id><journal-id journal-id-type="hwp">jcb</journal-id><journal-title-group><journal-title>The Journal of Cell Biology</journal-title></journal-title-group><issn pub-type="ppub">0021-9525</issn><issn pub-type="epub">1540-8140</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19651893</article-id><article-id pub-id-type="publisher-id">200905153</article-id><article-id pub-id-type="doi">10.1083/jcb.200905153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Articles</subject><subj-group><subject>Report</subject></subj-group></subj-group></article-categories><title-group><article-title>The role of BH3-only protein Bim extends beyond inhibiting Bcl-2&#x02013;like prosurvival proteins</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>M&#x000e9;rino</surname><given-names>Delphine</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Giam</surname><given-names>Maybelline</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Peter D.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Siggs</surname><given-names>Owen M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Heger</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>O'Reilly</surname><given-names>Lorraine A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>Jerry M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Strasser</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Erinna F.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fairlie</surname><given-names>Walter D.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bouillet</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3052, Australia</institution></aff><aff id="aff2"><label>2</label><institution>Department of Medical Biology, The University of Melbourne, Melbourne, Victoria 3010, Australia</institution></aff><author-notes><corresp>Correspondence to Philippe Bouillet: <email>bouillet@wehi.edu.au</email></corresp><fn><p>D. M&#x000e9;rino, M. Giam, and P.D. Hughes contributed equally to this paper.</p></fn><fn><p>O.M. Siggs' present address is Dept. of Genetics, The Scripps Research Institute, La Jolla, CA 92037.</p></fn></author-notes><pub-date pub-type="ppub"><day>10</day><month>8</month><year>2009</year></pub-date><volume>186</volume><issue>3</issue><fpage>355</fpage><lpage>362</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 M&#x000e9;rino et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="openaccess" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This article is distributed under the terms of an Attribution&#x02013;Noncommercial&#x02013;Share Alike&#x02013;No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.jcb.org/misc/terms.shtml">http://www.jcb.org/misc/terms.shtml</ext-link>). After six months it is available under a Creative Commons License (Attribution&#x02013;Noncommercial&#x02013;Share Alike 3.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Proteins of the Bcl-2 family are critical regulators of apoptosis, but how its BH3-only members activate the essential effectors Bax and Bak remains controversial. The indirect activation model suggests that they simply must neutralize all of the prosurvival Bcl-2 family members, whereas the direct activation model proposes that Bim and Bid must activate Bax and Bak directly. As numerous in vitro studies have not resolved this issue, we have investigated Bim's activity in vivo by a genetic approach. Because the BH3 domain determines binding specificity for Bcl-2 relatives, we generated mice having the Bim BH3 domain replaced by that of Bad, Noxa, or Puma. The mutants bound the expected subsets of prosurvival relatives but lost interaction with Bax. Analysis of the mice showed that Bim's proapoptotic activity is not solely caused by its ability to engage its prosurvival relatives or solely to its binding to Bax. Thus, initiation of apoptosis in vivo appears to require features of both models.</p></abstract></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>A pivotal step in apoptosis is activation of Bax and Bak. It leads to mitochondrial outer membrane permeabilization (MOMP) and the release to the cytosol of apoptogenic molecules such as cytochrome <italic>c</italic>, which provoke the proteolytic caspase cascade that dismantles the cell (<xref ref-type="bibr" rid="bib1">Adams and Cory, 2007</xref>). Prosurvival members of the Bcl-2 family (Bcl-2, Bcl-x<sub>L</sub>, Bcl-w, Mcl-1, and A1) prevent Bax/Bak activation and thereby preclude MOMP and apoptosis. The BH3-only proteins (e.g., Bim, Bid, Puma, Bad, and Noxa) promote cell death, but how they do so remains vigorously debated (<xref ref-type="bibr" rid="bib1">Adams and Cory, 2007</xref>; <xref ref-type="bibr" rid="bib8">Chipuk and Green, 2008</xref>). BH3-only proteins bind tightly and neutralize distinct subsets of prosurvival relatives (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>; <xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Certo et al., 2006</xref>), and the indirect activation model suggests that engaging all of them is necessary and seemingly sufficient to activate Bax and Bak (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Willis et al., 2005</xref>, <xref ref-type="bibr" rid="bib26">2007</xref>). In this model, the prosurvival Bcl-2 family members hold subpopulations of Bax and Bak molecules in check until BH3-only proteins free them. However, in cell-free studies, BH3 peptides from Bim or Bid and the active form of Bid (truncated Bid [tBid]) can activate Bax or Bak directly and cause MOMP (<xref ref-type="bibr" rid="bib17">Letai et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Certo et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Walensky et al., 2006</xref>; <xref ref-type="bibr" rid="bib10">Gavathiotis et al., 2008</xref>; <xref ref-type="bibr" rid="bib18">Lovell et al., 2008</xref>). The direct activation model posits that this interaction is critical; it suggests that the other BH3-only proteins, termed &#x0201c;sensitizers&#x0201d; (e.g., Bad and Noxa), function simply by binding the prosurvival proteins to free any sequestered Bim or tBid. Although the Puma BH3 has also been proposed to bind and activate Bax (<xref ref-type="bibr" rid="bib4">Cartron et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Kim et al., 2006</xref>; <xref ref-type="bibr" rid="bib9">Gallenne et al., 2009</xref>), other findings argue against that (<xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Certo et al., 2006</xref>; <xref ref-type="bibr" rid="bib26">Willis et al., 2007</xref>; <xref ref-type="bibr" rid="bib7">Chipuk et al., 2008</xref>; <xref ref-type="bibr" rid="bib2009">Jabbour et al., 2009</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold>BH3 replacements in Bim alter its binding profile.</bold> (A) Interactions between Bcl-2 family members show the rationale of our experiments. Bad binds Bcl-2, Bcl-x<sub>L</sub>, and Bcl-w, whereas Noxa binds only Mcl-1 and A1. Bim and Puma bind all of their prosurvival relatives, but Bim (the Bim<sub>S</sub> isoform) binds Bax, whereas Puma does not. (B) Amino acids 140&#x02013;161 of mouse Bim<sub>EL</sub> (red) were replaced by the BH3 sequences of mouse Bad, NoxaA, or Puma. Boxed sequences indicate the 26-mer peptides used to measure the affinities of the mutant BH3 peptides for mouse Bcl-x<sub>L</sub>, Mcl-1, and Bax. (C) Nanomolar affinities of the BH3 peptides for GST&#x02013;Bcl-x<sub>L</sub> and GST&#x02013;Mcl-1 as measured on an S51 biosensor. (D) Tests for binding of the same peptides to Bax. The dashed line corresponds to the method used to determine the IC50 value. Starting from the left side, 50% binding of Bim to Bax occurs when a concentration of 3.1 &#x000b5;M of peptide is present in the system. The horizontal dashed line is for the 50%, the place where it intersects with the curve determines the position of the vertical line, and the reading is made on the peptide concentration scale.</p></caption><graphic xlink:href="JCB_200905153_RGB_Fig1"/></fig><p>As the central issue of how the BH3-only proteins trigger apoptosis has not been resolved by the many experiments with overexpressed proteins in cell lines or the use of BH3 peptides in cell-free systems, we have devised a genetic approach to investigate this important question in vivo. We have focused on the <italic>Bim</italic> locus because, unlike Bid, Puma, Bad, or Noxa (<xref ref-type="bibr" rid="bib22">Strasser, 2005</xref>), its disruption markedly increases hematopoietic cell numbers (<xref ref-type="bibr" rid="bib3">Bouillet et al., 1999</xref>). Bim loss also prevents the fatal polycystic kidney disease (PKD) and other degenerative disorders provoked by the abnormal cell attrition in the absence of Bcl-2 (<xref ref-type="bibr" rid="bib2">Bouillet et al., 2001</xref>). Bim is an unstructured polypeptide (<xref ref-type="bibr" rid="bib11">Hinds et al., 2007</xref>), and its binding specificity, like that of other BH3-only proteins, appears to be defined entirely by its BH3 domain (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>). We have altered its specificity by engineering knockin mouse strains having its BH3 domain replaced by that of Bad (Bim<sup>Bad</sup>), Noxa (Bim<sup>Noxa</sup>), or Puma (Bim<sup>Puma</sup>). The Bim BH3 can bind to all of its prosurvival relatives and weakly to Bax; the Puma BH3 also engages all of the prosurvival proteins, whereas the Bad and Noxa BH3 bind only subsets of them and not Bax (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>).</p><p>These mice allow tests within the physiological setting of whether Bim's proapoptotic function relies upon engaging Bax or all of its prosurvival relatives. Surprisingly, the observed phenotypes of the Bim BH3 mutant mice in both the wild-type (WT) and sensitized Bcl-2&#x02013;deficient background do not entirely fit with either model and suggest that aspects of each must hold to fully account for Bim's ability to initiate programmed cell death.</p></sec><sec><title>Results and discussion</title><sec><title>Generation of mice with altered Bim specificities</title><p><xref ref-type="fig" rid="fig1">Fig. 1 B</xref> depicts the Bim mutations generated. Because the binding affinity of a BH3-only protein determines its proapoptotic potential (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Certo et al., 2006</xref>; <xref ref-type="bibr" rid="bib15">Lee et al., 2008</xref>), we determined the affinities of 26-mer peptides spanning the mutant BH3 domains for Bcl-x<sub>L</sub> and Mcl-1 (<xref ref-type="fig" rid="fig1">Fig. 1 C</xref>). The Bim<sup>Bad</sup> and Bim<sup>Puma</sup> peptides bound at least as tightly as the WT Bim peptide to Bcl-x<sub>L</sub>, as did the Bim<sup>Puma</sup> peptide to Mcl-1. The Bim<sup>Noxa</sup> peptide bound Mcl-1 approximately fivefold less tightly than its WT Bim counterpart, which is in keeping with the lower affinity of Noxa than Bim for Mcl-1 (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>). Similar tests of the binding of the peptides to Bax (<xref ref-type="fig" rid="fig1">Fig. 1 D</xref>) showed that WT Bim peptide bound full-length Bax, albeit much more weakly (IC50 = 3.1 &#x000b5;M) than the low nanomolar binding to its prosurvival relatives, but neither the Bim<sup>Bad</sup>, Bim<sup>Noxa</sup>, nor Bim<sup>Puma</sup> peptide bound Bax detectably (IC50 &#x0003e; 20 &#x000b5;M; <xref ref-type="fig" rid="fig1">Fig. 1 D</xref>).</p><p>Mice homozygous for each mutation (designated <italic>Bim<sup>B/B</sup></italic>, <italic>Bim<sup>N/N</sup></italic>, and <italic>Bim<sup>P/P</sup></italic>) were outwardly indistinguishable from WT littermates. The knockin mutations do not alter the exon structure, splicing sites, or any Bim motif (e.g., phosphorylation or ubiquitination sites) implicated in regulating its level or activity (<xref ref-type="fig" rid="fig2">Fig. 2 A</xref>). Accordingly, Western blots of thymocyte lysates revealed that the Bim<sup>Bad</sup> and Bim<sup>Puma</sup> mice had WT Bim levels, and those in Bim<sup>Noxa</sup> mice appeared only slightly lower (<xref ref-type="fig" rid="fig2">Fig. 2 B</xref>). The levels of other family members (Bcl-2, Bcl-x<sub>L</sub>, Mcl-1, and Bax) were unaffected (<xref ref-type="fig" rid="fig2">Fig. 2 B</xref>). As expected, ionomycin increased Bim expression comparably in both the mutant and WT thymocytes (<xref ref-type="fig" rid="fig2">Fig. 2 C</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><bold>BH3 replacements in Bim change its binding profile.</bold> (A) Knockin strategy for the BH3 replacements (not to scale). Note that the introduced sequences do not overlap the splice sites. (B) Normal expression of the Bim mutant proteins and Bcl-2 family members in the thymi of 6&#x02013;8-wk-old knockin animals. Triton X-100 lysates of 4 &#x000d7; 10<sup>6</sup> cells were loaded per lane. The Western blots show samples from two animals per genotype. Hsp70 provided a loading control. (C) Immunoprecipitations (IPs) from thymocyte extracts of the indicated genotypes reveal the binding of WT Bim and the mutants to prosurvival relatives. (D) Test for binding of WT Bim and the mutants to Bax. HA-tagged Bim<sub>L</sub> (L) and Bim<sub>S</sub> (S) isoforms of each protein were overexpressed in COS-7 cells, lysates were prepared in buffer containing Triton X-100, which promotes heterodimerization, and association with endogenous Bax was tested using an anti-HA antibody&#x02013;coupled affinity resin. Only WT Bim<sub>S</sub> showed significant binding to Bax. (C and D) The asterisks indicate nonspecific bands caused by the secondary antibody. (B&#x02013;D) Molecular mass is shown in kilodaltons.</p></caption><graphic xlink:href="JCB_200905153_RGB_Fig2"/></fig><p>We verified that the mutant Bim proteins had the expected binding profiles (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>) by coimmunoprecipitation from thymocyte lysates. Indeed, Bim<sup>Bad</sup> bound Bcl-2 and Bcl-x<sub>L</sub> but not Mcl-1, and Bim<sup>Noxa</sup> bound Mcl-1 but not Bcl-2 or Bcl-x<sub>L</sub>, whereas Bim<sup>Puma</sup>, like WT Bim, bound all of these prosurvival proteins (<xref ref-type="fig" rid="fig2">Fig. 2 C</xref>). Because the only mouse Bim isoform that binds Bax detectably (in Triton X-100&#x02013;containing buffers) is Bim<sub>S</sub> (<xref ref-type="bibr" rid="bib26">Willis et al., 2007</xref>), the rarest of the three main Bim isoforms in all tissues (<xref ref-type="bibr" rid="bib20">O'Connor et al., 1998</xref>), we overexpressed the L and S isoforms of WT Bim and each Bim BH3 mutant in COS cells and tested their binding to endogenous Bax. As expected, WT Bim<sub>S</sub> but not WT Bim<sub>L</sub> bound some Bax, but neither form of Bim<sup>Bad</sup>, Bim<sup>Noxa</sup>, or Bim<sup>Puma</sup> bound detectable Bax (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>), which is in accord with the BH3 peptide&#x02013;binding data (<xref ref-type="fig" rid="fig1">Fig. 1 D</xref>). Thus, none of the Bim mutants should have direct activator function for Bax. No binding of any Bim isoform to Bak has been detected (<xref ref-type="bibr" rid="bib26">Willis et al., 2007</xref>).</p></sec><sec><title>Engaging all prosurvival relatives is necessary but not sufficient for full Bim proapoptotic function</title><p>As Bim plays major roles in hemopoietic homeostasis, Bim-null mice accumulate excess white blood cells (WBCs) and splenocytes (<xref ref-type="bibr" rid="bib3">Bouillet et al., 1999</xref>). To determine whether the BH3 replacement mutants retain all, some or none of Bim's proapoptotic activity, we compared their WBC numbers and spleen weight and those of mice bred to bear both a Bim<sup>Bad</sup> and a Bim<sup>Noxa</sup> allele (<italic>Bim<sup>B/N</sup></italic> animals) with the levels in WT, <italic>Bim<sup>+/&#x02212;</sup></italic>, and <italic>Bim<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). For all genotypes, WBC numbers mirrored spleen weight, as expected. <xref ref-type="fig" rid="fig3">Fig. 3 B</xref> compares the observed phenotypes with those predicted by the indirect and direct activation models.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><bold>BH3 replacements in Bim restrict its function.</bold> (A) WBC numbers in at least 16 mice of each genotype were determined on an ADVIA blood analyzer. Spleens of at least eight mice per genotype were weighed. Means &#x000b1; SEM are shown, and the significance of differences from WT cells was determined by two-tailed <italic>t</italic> tests (*, P &#x0003c; 0.05; ***, P &#x0003c; 0.001). (B) The phenotypes of the BH3 substitution mutants predicted by the indirect and direct activation models and the observed phenotype. The prediction by the direct activation model for Bim<sup>Puma</sup> depends on whether Puma is an activator, which remains in dispute (see Introduction).</p></caption><graphic xlink:href="JCB_200905153_LW_Fig3"/></fig><p>Consistent with the inability of Bim<sup>Bad</sup> or Bim<sup>Noxa</sup> to bind certain prosurvival relatives (<xref ref-type="fig" rid="fig1">Figs. 1</xref> and <xref ref-type="fig" rid="fig2">2</xref>), each had reduced proapoptotic function: both <italic>Bim<sup>B/B</sup></italic> and <italic>Bim<sup>N/N</sup></italic> mice had significantly more WBCs and greater spleen weight than WT mice (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). Thus, Bim<sup>Bad</sup> and Bim<sup>Noxa</sup> are hypomorphs, as expected from the indirect activation model (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). Comparison with the <italic>Bim<sup>&#x02212;/&#x02212;</sup></italic> mice clearly shows that each retained substantial proapoptotic activity, indeed more than half of the WT Bim activity (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). As neither Bim<sup>Bad</sup> nor Bim<sup>Noxa</sup> binds Bax (<xref ref-type="fig" rid="fig1">Figs. 1 D</xref> and <xref ref-type="fig" rid="fig2">2 D</xref>), this conflicts with the direct activation model (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). Overall, these results suggest that neutralization of any of the prosurvival proteins increases the odds that many cells will undergo apoptosis. Surprisingly, Bim<sup>Puma</sup> also proved to be a hypomorph because the <italic>Bim<sup>P/P</sup></italic> mice had significant albeit smaller increases in their WBCs (P = 0.02; <italic>n</italic> = 39) and spleen weight (P = 0.019; <italic>n</italic> = 13) over WT mice (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). Thus, although Bim<sup>Puma</sup> and WT Bim bind all of the prosurvival members with comparable high affinity (<xref ref-type="fig" rid="fig1">Figs. 1 C</xref> and <xref ref-type="fig" rid="fig2">2 C</xref>), Bim<sup>Puma</sup> is somewhat less potent than WT Bim, a finding which is discordant with both models (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>).</p><p>We reasoned that if antagonizing prosurvival Bcl-2 family members was the sole function of Bim, combining Bim<sup>Bad</sup> and Bim<sup>Noxa</sup> should reconstitute its full function (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>), and thus, the <italic>Bim<sup>B/N</sup></italic> mice might have a WT phenotype (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). However, they also presented with significantly greater WBC numbers and spleen weights (P &#x0003c; 0.0001) than WT mice (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>), which is in conflict with indirect activation. A caveat is that these mice possess only a single allele of each Bim BH3 mutant; thus, any cells relying entirely on Bcl-2/Bcl-x<sub>L</sub>/Bcl-w or entirely on Mcl-1/A1 for their survival would have an advantage because they would behave as if they had only half a dose of Bim. In any case, the retention of substantial proapoptotic function by Bim mutants that do not bind Bax argues that direct activation of Bax cannot be the sole essential proapoptotic function of Bim (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>).</p><p>Unlike the long-term effects on cell death in vivo in <xref ref-type="fig" rid="fig3">Fig. 3 A</xref>, in vitro survival assays with several cytotoxic stimuli on sorted thymocyte and B cell populations from mice of all of the genotypes (illustrated for CD4<sup>+</sup>8<sup>+</sup> thymocytes in <ext-link ext-link-type="uri" xlink:href="http://www.jcb.org/cgi/content/full/jcb.200905153/DC1">Fig. S1</ext-link>) revealed no significant differences between the death rates of <italic>Bim<sup>B/B</sup></italic>, <italic>Bim<sup>N/N</sup></italic>, <italic>Bim<sup>B/N</sup></italic>, <italic>Bim<sup>P/P</sup></italic>, and WT cells. The comparable killing by mutant and WT Bim with certain stimuli in ex vivo assays (Fig. S1) suggests that distinguishing subtle differences in their apoptotic potential requires analysis of long-term effects in vivo. The discrepancy between the in vivo and in vitro results probably reflects both the substantial activity of the mutants and the difficulty of fully replicating in vivo stresses in vitro.</p></sec><sec><title>The Bim mutants ameliorate or prevent the PKD and lymphopenia provoked by Bcl-2 deficiency</title><p>In the absence of Bcl-2, Bim drives the attrition of several tissues (<xref ref-type="bibr" rid="bib2">Bouillet et al., 2001</xref>). On the C57BL/6 background, Bcl-2&#x02013;deficient mice are runty (<xref ref-type="fig" rid="fig4">Fig. 4 A</xref>), profoundly lymphopenic, and usually die by 6&#x02013;7 wk of age from the renal failure induced by PKD, but all of these degenerative disorders are prevented by loss of Bim, and even loss of a single <italic>Bim</italic> allele precludes the PKD and renders the mice as healthy as WT or <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>&#x02212;/&#x02212;</sup></italic> animals (<xref ref-type="bibr" rid="bib2">Bouillet et al., 2001</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><p><bold>BH3 mutations in Bim ameliorate the degenerative disorders of Bcl-2&#x02013;deficient mice.</bold> (A) A 40-d-old <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mouse and its WT littermate are shown above a 120-d-old <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mouse and a WT mouse of that age. (B) Kidneys of <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice show only mild signs of PKD compared with <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> kidneys. (C) Normal spleen structure in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice versus the atrophied <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> spleen. (D) Weights of WT and Bcl-2&#x02013;null mice at 40 and 80 d showing that the Bcl-2&#x02013;null Bim<sup>Bad</sup> and Bim<sup>Noxa</sup> animals grow normally, whereas growth of the Bim<sup>Puma</sup> mice is retarded (P &#x0003c; 0.0001) but much less so than the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> animals, which have all died by 80 d (cross). (E) Blood composition for at least 10 mice per genotype was analyzed on an ADVIA blood analyzer, except for the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> animals (<italic>n</italic> = 4). Spleens from at least eight mice per genotype were weighed, except for the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> animals (<italic>n</italic> = 5). Means &#x000b1; SEM and the significance of differences (by two-tailed <italic>t</italic> test) from the values in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> animals (*, P &#x0003c; 0.05; ***, P &#x0003c; 0.001) are shown. Bars, 1 mm.</p></caption><graphic xlink:href="JCB_200905153_RGB_Fig4"/></fig><p>Because Bim<sup>Bad</sup>, Bim<sup>Noxa</sup>, and Bim<sup>Puma</sup> all behaved as hypomorphs (<xref ref-type="fig" rid="fig3">Fig. 3</xref>), we reasoned that they might ameliorate or even prevent some of the disorders in Bcl-2&#x02013;deficient mice. Indeed, breeding Bcl-2&#x02013;null animals expressing each mutant revealed that no <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/B</sup></italic> or <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>N/N</sup></italic> mice developed PKD. These animals grew normally (<xref ref-type="fig" rid="fig4">Fig. 4 D</xref>) and had normal kidney histology (<ext-link ext-link-type="uri" xlink:href="http://www.jcb.org/cgi/content/full/jcb.200905153/DC1">Fig. S2</ext-link>). They differed from Bcl-2&#x02013;proficient littermates only by turning gray at 5&#x02013;7 wk of age, as expected if some Bim function remains in melanocytes (<xref ref-type="bibr" rid="bib2">Bouillet et al., 2001</xref>). Thus, Bim<sup>Bad</sup> and Bim<sup>Noxa</sup> also retained partial Bim function in a nonhemopoietic cell type, which is in accord with indirect but not direct activation (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>).</p><p>Remarkably, although the growth of <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice was retarded (<xref ref-type="fig" rid="fig4">Fig. 4, A and D</xref>), most of these animals (<italic>n</italic> = 24) became healthy adults. These mice were smaller than WT mice, and their kidneys showed mild signs of PKD (<xref ref-type="fig" rid="fig4">Fig. 4 B</xref> and Fig. S2 A), but it progressed slowly, and they could live up to 300 d, whereas all 35&#x02013;40-d-old <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice exhibited large kidney cysts (<xref ref-type="fig" rid="fig4">Fig. 4 B</xref>) and died by 50 d. The less severe PKD in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice than in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice confirms that Bim<sup>Puma</sup> is less potent than WT Bim in these cells.</p><p><italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice have very small spleens (5&#x02013;10 mg vs. 60&#x02013;100 mg in WT) with very few lymphoid follicles (white pulp) but many apoptotic cells (<xref ref-type="fig" rid="fig4">Fig. 4, C and E</xref>; and Fig. S2). However, splenic structure was normal in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/B</sup></italic>, <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>N/N</sup></italic>, and <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/N</sup></italic> mice and, remarkably, even in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> animals (<xref ref-type="fig" rid="fig4">Fig. 4 C</xref> and <ext-link ext-link-type="uri" xlink:href="http://www.jcb.org/cgi/content/full/jcb.200905153/DC1">Fig. S3</ext-link>). As in the Bcl-2&#x02013;proficient animals (<xref ref-type="fig" rid="fig2">Fig. 2</xref>), spleen weights and WBC numbers varied in parallel with genotype, and all of the mutants behaved as hypomorphic Bim alleles (<xref ref-type="fig" rid="fig4">Fig. 4 E</xref>). Also, the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/N</sup></italic> spleens were much heavier than those in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice (P &#x0003c; 0.0001) or even <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/&#x02212;</sup></italic> animals (P &#x0003c; 0.0001), and WBCs were approximately sixfold more abundant in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/N</sup></italic> than in <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice (P = 0.0003). The greater potency of WT Bim or even of a single WT Bim allele than the combination of Bim<sup>Bad</sup> plus Bim<sup>Noxa</sup> conflicts with the indirect activation model (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>).</p><p>Similarly, the spleens of <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice were heavier than the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> spleens (<xref ref-type="fig" rid="fig4">Fig. 4 E</xref>) and displayed less apoptosis (Fig. S3). The <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> mice also had more WBCs than the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice (P = 0.018) but decidedly fewer WBCs and lower spleen weights than the <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>B/B</sup></italic> or <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>N/N</sup></italic> animals (<xref ref-type="fig" rid="fig4">Fig. 4 E</xref>). Thus, Bim<sup>Puma</sup> again is the mutant most similar to WT Bim, which is in accord with its ability to engage all of the prosurvival proteins (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>), emphasizing this as a critical part of Bim function. Nevertheless, Bim<sup>Puma</sup> is less potent than WT Bim despite binding to the prosurvival proteins with similar affinity (<xref ref-type="fig" rid="fig1">Fig. 1 C</xref>). Thus, WT Bim has a function beyond engaging all of its prosurvival relatives.</p></sec><sec><title>Aspects of both indirect and direct activation appear to contribute to programmed cell death in vivo</title><p>Our interpretation of these findings on the role of Bim in programmed cell death within the intact animal is depicted in <xref ref-type="fig" rid="fig5">Fig. 5</xref>. They show first that restricting Bim's binding spectrum for Bcl-2&#x02013;like prosurvival proteins indeed limits its proapoptotic potential, which is consistent with the indirect model for Bax/Bak activation (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Willis et al., 2007</xref>). Thus, both Bim<sup>Bad</sup> and Bim<sup>Noxa</sup>, which each bind only a subset of the prosurvival proteins (<xref ref-type="fig" rid="fig1">Figs. 1</xref> and <xref ref-type="fig" rid="fig4">4 B</xref>), were less potent than WT Bim, as shown both by elevated hematopoietic cell numbers (<xref ref-type="fig" rid="fig3">Figs. 3</xref> and <xref ref-type="fig" rid="fig4">4 E</xref>) and their prevention of the PKD and lymphopenia provoked by Bcl-2 loss (<xref ref-type="fig" rid="fig4">Fig. 4</xref> and Fig. S2). As neither Bim<sup>Bad</sup> nor Bim<sup>Noxa</sup> binds all of the prosurvival proteins, inactivation of any of them must increase the probability that a cell will undergo apoptosis (<xref ref-type="fig" rid="fig5">Fig. 5 B</xref>). Notably, although neither the Bad nor the Noxa BH3 binds to Bax (<xref ref-type="fig" rid="fig1">Figs. 1 D</xref> and <xref ref-type="fig" rid="fig2">2 D</xref>), both Bim<sup>Bad</sup> and Bim<sup>Noxa</sup> retained substantial proapoptotic activity, at least in hematopoietic cells and melanocytes, indicating that engagement of Bax is not essential for Bim function (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><p><bold>Model for the initiation of apoptosis by Bim.</bold> (A) In the absence of Bim, Bax is kept in check by both subsets of its prosurvival relatives (&#x0201c;Bcl&#x0201d; represents Bcl-2, Bcl-x<sub>L</sub>, and Bcl-w; &#x0201c;Mcl&#x0201d; represents Mcl-1 and A1; <xref ref-type="bibr" rid="bib26">Willis et al., 2007</xref>). (B) In cells expressing Bim<sup>Bad</sup>, the Bcl subset is neutralized, but the Mcl subset still partially restrains Bax and limits its induction of apoptosis. Conversely, in Bim<sup>Noxa</sup> mice, Bax is partly restrained by the Bcl proteins. (C) In mice expressing Bim<sup>Puma</sup>, all of the prosurvival proteins are neutralized, allowing the unrestrained Bax to induce very substantial apoptosis. (D) Unlike the three Bim BH3 mutants, WT Bim is proposed to also bind transiently to Bax, giving maximal activity.</p></caption><graphic xlink:href="JCB_200905153_RGB_Fig5"/></fig><p>Because Bim<sup>Puma</sup> and the combination of Bim<sup>Bad</sup> plus Bim<sup>Noxa</sup> can engage all of the prosurvival Bcl-2 family members (<xref ref-type="fig" rid="fig1">Figs. 1</xref> and <xref ref-type="fig" rid="fig5">5 C</xref>), the indirect activation model predicts that both should have full WT Bim function (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). Instead, leukocytes accumulated abnormally in both <italic>Bim<sup>P/P</sup></italic> and <italic>Bim<sup>B/N</sup></italic> mice (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). The far greater health of <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>P/P</sup></italic> than <italic>Bcl-2<sup>&#x02212;/&#x02212;</sup>Bim<sup>+/+</sup></italic> mice (<xref ref-type="fig" rid="fig4">Fig. 4</xref>) also clearly shows that Bim<sup>Puma</sup> is less potent than WT Bim. Thus, binding to prosurvival Bcl-2 family members does not fully account for Bim's proapoptotic activity (<xref ref-type="fig" rid="fig5">Fig. 5 D</xref>). This conclusion could only be reached by studying the long-term effects of altering Bim's specificity in a physiological context.</p><p>The most plausible additional Bim BH3 function is (transient) engagement of Bax (<xref ref-type="fig" rid="fig5">Fig. 5 D</xref>; <xref ref-type="bibr" rid="bib17">Letai et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>). The WT but not the mutant Bim BH3 peptide bound measurably to Bax (<xref ref-type="fig" rid="fig1">Fig. 1 D</xref>), and full-length Bim<sub>S</sub> but not Bim<sub>L</sub> coimmunoprecipitated with Bax (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>). Because WT Bim<sub>S</sub> but neither the S nor L isoform of Bim<sup>Bad</sup>, Bim<sup>Noxa</sup>, or Bim<sup>Puma</sup> bound Bax detectably (<xref ref-type="fig" rid="fig2">Fig. 2 D</xref>), engagement of Bax by Bim<sub>S</sub> might account for the additional Bim function (<xref ref-type="bibr" rid="bib24">Weber et al., 2007</xref>). Alternatively, the more abundant Bim<sub>L</sub> and Bim<sub>EL</sub> might also do so but be more quickly displaced by the resulting Bax conformational changes so that those complexes cannot readily be detected. This conclusion is in accord with recent evidence that a stabilized Bim BH3 peptide can interact weakly with Bax and provoke its activation and oligomerization (<xref ref-type="bibr" rid="bib10">Gavathiotis et al., 2008</xref>).</p><p>Thus, our results suggest that the ability of Bim to engage its prosurvival relatives accounts for much of its proapoptotic function in vivo (<xref ref-type="fig" rid="fig5">Fig. 5, B and C</xref>) but that full Bim activity requires a distinct function (<xref ref-type="fig" rid="fig5">Fig. 5 D</xref>), most likely its oft proposed but elusive ability to transiently engage Bax (<xref ref-type="bibr" rid="bib17">Letai et al., 2002</xref>; <xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Certo et al., 2006</xref>; <xref ref-type="bibr" rid="bib23">Walensky et al., 2006</xref>; <xref ref-type="bibr" rid="bib10">Gavathiotis et al., 2008</xref>). That ability is most likely shared by tBid (<xref ref-type="bibr" rid="bib14">Kuwana et al., 2005</xref>; <xref ref-type="bibr" rid="bib18">Lovell et al., 2008</xref>), although tBid is more likely to amplify rather than initiate an apoptotic response because Bid needs to be activated by caspases. The Puma BH3 probably lacks direct activator function because Bim<sup>Puma</sup> proved a significantly less potent apoptosis initiator than WT Bim in both leucocytes and the kidney (<xref ref-type="fig" rid="fig4">Fig. 4</xref> and Figs. S2 and S3), and neither full length Bim<sup>Puma</sup> nor the corresponding BH3 peptide bound detectably to Bax (<xref ref-type="fig" rid="fig1">Figs. 1 D</xref> and <xref ref-type="fig" rid="fig2">2 D</xref>). Thus, initiation of programmed cell death seems to require features of both the indirect and direct models. These findings will have important consequences for the design of BH3 mimetic drugs (<xref ref-type="bibr" rid="bib21">Oltersdorf et al., 2005</xref>) of the second generation.</p></sec></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Generation of Bim BH3 replacement knockin mice</title><p>The Bim BH3 (in exon 5) was replaced by the mouse Bad, NoxaA, or Puma BH3 domain by site-directed mutagenesis using PCR. A loxP-PGKneo-loxP cassette was inserted 840 bp downstream of exon 5 for selection of homologous recombinants. DNA constructs were electroporated into C57BL/6-derived Bruce-4 embryonic stem cells (<xref ref-type="bibr" rid="bib16">Lemckert et al., 1997</xref>). The <italic>neo</italic> cassette was removed by crossing the mice to <italic>cre deleter</italic> transgenic mice, and the <italic>cre</italic> transgene was then eliminated by crossing to C57BL/6 mice. All of the mice analyzed were devoid of <italic>neo</italic> and <italic>cre</italic>. The <italic>Bcl-2<sup>+/&#x02212;</sup></italic> mice (<xref ref-type="bibr" rid="bib19">Nakayama et al., 1994</xref>) and <italic>Bim<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref ref-type="bibr" rid="bib3">Bouillet et al., 1999</xref>) used in this study had been serially backcrossed with C57BL/6 mice for &#x0003e;20 generations before being intercrossed to produce homozygotes. Peripheral blood erythrocytes and leukocytes were enumerated using an ADVIA hematology system (Bayer). All animal experiments followed the guidelines of the Melbourne Directorate Animal Ethics Committee.</p></sec><sec><title>Affinity measurements</title><p>The affinity of 26-mer BH3 peptides for recombinant murine Bcl-x<sub>L</sub>&#x00394;C25 and murine Mcl-1&#x00394;N151&#x00394;C23 was determined using a biosensor (model S51; Biacore) as previously described (<xref ref-type="bibr" rid="bib15">Lee et al., 2008</xref>). The recombinant proteins were expressed and purified as GST fusion proteins using standard techniques. Synthetic peptides (&#x0003e;90% purity) were purchased from Mimotopes.</p><p>Full-length Bax was expressed as a chitin-binding protein fusion and purified by chitin affinity chromatography followed by gel filtration chromatography. Binding of Bax to BH3 peptides was determined by solution competition assays using a Biacore 3000 instrument as described previously (<xref ref-type="bibr" rid="bib6">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">Willis et al., 2005</xref>, <xref ref-type="bibr" rid="bib26">2007</xref>). In brief, 1 &#x000b5;M Bax was incubated with increasing concentrations of synthetic peptide in Biacore running buffer (10 mM Hepes, 150 mM NaCl, 3.4 mM EDTA, and 0.005% [vol/vol] Tween 20, pH 7.4) containing 1% (wt/vol) octyl-glucoside before injection onto a CM5 Biacore chip on which the Bim BH3 and the inert Bim4E peptides were immobilized by amine coupling. The specific response was determined by subtracting the response on the Bim4E channel from that on the WT Bim BH3 channel.</p></sec><sec><title>Immunoprecipitation and Western blotting</title><p>Cell lysates were prepared in lysis buffer (20 mM Tris, pH 7.4, 135 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EGTA, 10% glycerol, and 1% Triton X-100) supplemented with complete protease inhibitor cocktail (Roche). Immunoprecipitation was performed using a rat monoclonal antibody to Bim (3C5; Enzo Biochem, Inc.), which recognizes an N-terminal epitope present in all isoforms and mutants of Bim that were used. Proteins were resolved by SDS-PAGE and detected on Western blots with rat monoclonal antibodies to Bim (14A8 or 3C5; Enzo Biochem, Inc.) or Bmf (17A9; Enzo Biochem, Inc.), hamster monoclonal antibodies to mouse Bcl-2 (3F11; a gift from S. Korsmeyer; Dana-Farber Cancer Institute, Boston, MA), and rabbit polyclonal antibodies to Bax (Millipore), Bcl-x<sub>L</sub> (BD), or Mcl-1 (Rockland), followed by ECL (GE Healthcare).</p></sec><sec><title>Immunofluorescent staining, FACS analysis, cell sorting, tissue culture, and cell survival assays</title><p>Leukocyte subpopulations were identified and sorted as described previously (<xref ref-type="bibr" rid="bib3">Bouillet et al., 1999</xref>). Cells were incubated in medium alone (no treatment; i.e., cytokine deprivation) or treated with 1 &#x000b5;g/ml ionomycin, 10 ng/ml PMA, or 1 &#x000b5;M ABT-737 (<xref ref-type="bibr" rid="bib21">Oltersdorf et al., 2005</xref>). Cell survival was quantified daily by staining with 2 &#x000b5;g/ml propidium iodide and FACS analysis.</p></sec><sec><title>Online supplemental material</title><p>Fig. S1 shows the survival of CD4<sup>+</sup>8<sup>+</sup> thymocytes from <italic>Bim<sup>&#x02212;/&#x02212;</sup></italic>, <italic>Bim<sup>+/&#x02212;</sup></italic>, <italic>Bim<sup>B/B</sup></italic>, <italic>Bim<sup>N/N</sup></italic>, <italic>Bim<sup>P/P</sup></italic>, <italic>Bim<sup>B/N</sup></italic>, and WT mice in vitro after treatment with different apoptotic stimuli. Fig. S2 shows that BH3-replacement mutations prevent the development of PKD and spleen atrophy in Bcl-2&#x02013;deficient mice. Fig. S3 shows that BH3-replacement mutations preclude the excessive apoptosis in the spleen of Bcl-2&#x02013;deficient mice. Online supplemental material is available at <ext-link ext-link-type="uri" xlink:href="http://www.jcb.org/cgi/content/full/jcb.200905153/DC1">http://www.jcb.org/cgi/content/full/jcb.200905153/DC1</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplemental Material]&#x000a0;</title></caption><media mimetype="text" mime-subtype="html" xlink:href="jcb.200905153_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="jcb.200905153_1.pdf"/></supplementary-material></sec></body><back><ack><p>We thank M. Robati and H. Yang for technical assistance, G. Siciliano, J. McSween, and E. Sutherland for mouse care, J. Corbin for automated blood analysis, B. Helbert and C. Young for genotyping, and Dr. S. Mihajlovic, E. Tsui, A. Hasanein, V. Babo, and K. Weston for histological sections. We are grateful to Prof. P. Colman and Dr. D.C.S. Huang for comments.</p><p>This work was supported by grants from the Australian National Health and Medical Research Council (461221, Independent Research Institutes Infrastructure Support Scheme grant 361646, and Career Development Award), the Victorian State Government (Operational Infrastructure Support grant), Cancer Council Victoria, the Leukemia and Lymphoma Society (Specialized Center of Research grant 7015), the Australian Research Council (to D. M&#x000e9;rino), and the Viertel Charitable Foundation (to P. Bouillet).</p></ack><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Cory</surname><given-names>S.</given-names></name></person-group><year>2007</year><article-title>Bcl-2-regulated apoptosis: mechanism and therapeutic potential</article-title>.<source>Curr. Opin. Immunol.</source><volume>19</volume>:<fpage>488</fpage>&#x02013;<lpage>496</lpage><pub-id pub-id-type="pmid">17629468</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouillet</surname><given-names>P.</given-names></name><name><surname>Metcalf</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>D.C.S.</given-names></name><name><surname>Tarlinton</surname><given-names>D.M.</given-names></name><name><surname>Kay</surname><given-names>T.W.H.</given-names></name><name><surname>K&#x000f6;ntgen</surname><given-names>F.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name></person-group><year>1999</year><article-title>Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity</article-title>.<source>Science.</source><volume>286</volume>:<fpage>1735</fpage>&#x02013;<lpage>1738</lpage><pub-id pub-id-type="pmid">10576740</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouillet</surname><given-names>P.</given-names></name><name><surname>Cory</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>L.-C.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name></person-group><year>2001</year><article-title>Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim</article-title>.<source>Dev. Cell.</source><volume>1</volume>:<fpage>645</fpage>&#x02013;<lpage>653</lpage><pub-id pub-id-type="pmid">11709185</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartron</surname><given-names>P.F.</given-names></name><name><surname>Gallenne</surname><given-names>T.</given-names></name><name><surname>Bougras</surname><given-names>G.</given-names></name><name><surname>Gautier</surname><given-names>F.</given-names></name><name><surname>Manero</surname><given-names>F.</given-names></name><name><surname>Vusio</surname><given-names>P.</given-names></name><name><surname>Meflah</surname><given-names>K.</given-names></name><name><surname>Vallette</surname><given-names>F.M.</given-names></name><name><surname>Juin</surname><given-names>P.</given-names></name></person-group><year>2004</year><article-title>The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA</article-title>.<source>Mol. Cell.</source><volume>16</volume>:<fpage>807</fpage>&#x02013;<lpage>818</lpage><pub-id pub-id-type="pmid">15574335</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Certo</surname><given-names>M.</given-names></name><name><surname>Moore Vdel</surname><given-names>G.</given-names></name><name><surname>Nishino</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Korsmeyer</surname><given-names>S.</given-names></name><name><surname>Armstrong</surname><given-names>S.A.</given-names></name><name><surname>Letai</surname><given-names>A.</given-names></name></person-group><year>2006</year><article-title>Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members</article-title>.<source>Cancer Cell.</source><volume>9</volume>:<fpage>351</fpage>&#x02013;<lpage>365</lpage><pub-id pub-id-type="pmid">16697956</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Willis</surname><given-names>S.N.</given-names></name><name><surname>Wei</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>B.J.</given-names></name><name><surname>Fletcher</surname><given-names>J.I.</given-names></name><name><surname>Hinds</surname><given-names>M.G.</given-names></name><name><surname>Colman</surname><given-names>P.M.</given-names></name><name><surname>Day</surname><given-names>C.L.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Huang</surname><given-names>D.C.S.</given-names></name></person-group><year>2005</year><article-title>Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function</article-title>.<source>Mol. Cell.</source><volume>17</volume>:<fpage>393</fpage>&#x02013;<lpage>403</lpage><pub-id pub-id-type="pmid">15694340</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chipuk</surname><given-names>J.E.</given-names></name><name><surname>Green</surname><given-names>D.R.</given-names></name></person-group><year>2008</year><article-title>How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?</article-title><source>Trends Cell Biol.</source><volume>18</volume>:<fpage>157</fpage>&#x02013;<lpage>164</lpage><pub-id pub-id-type="pmid">18314333</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chipuk</surname><given-names>J.E.</given-names></name><name><surname>Fisher</surname><given-names>J.C.</given-names></name><name><surname>Dillon</surname><given-names>C.P.</given-names></name><name><surname>Kriwacki</surname><given-names>R.W.</given-names></name><name><surname>Kuwana</surname><given-names>T.</given-names></name><name><surname>Green</surname><given-names>D.R.</given-names></name></person-group><year>2008</year><article-title>Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>105</volume>:<fpage>20327</fpage>&#x02013;<lpage>20332</lpage><pub-id pub-id-type="pmid">19074266</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallenne</surname><given-names>T.</given-names></name><name><surname>Gautier</surname><given-names>F.</given-names></name><name><surname>Oliver</surname><given-names>L.</given-names></name><name><surname>Hervouet</surname><given-names>E.</given-names></name><name><surname>Noel</surname><given-names>B.</given-names></name><name><surname>Hickman</surname><given-names>J.A.</given-names></name><name><surname>Geneste</surname><given-names>O.</given-names></name><name><surname>Cartron</surname><given-names>P.F.</given-names></name><name><surname>Vallette</surname><given-names>F.M.</given-names></name><name><surname>Manon</surname><given-names>S.</given-names></name><name><surname>Juin</surname><given-names>P.</given-names></name></person-group><year>2009</year><article-title>Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members</article-title>.<source>J. Cell Biol.</source><volume>185</volume>:<fpage>279</fpage>&#x02013;<lpage>290</lpage><pub-id pub-id-type="pmid">19380879</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavathiotis</surname><given-names>E.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Davis</surname><given-names>M.L.</given-names></name><name><surname>Pitter</surname><given-names>K.</given-names></name><name><surname>Bird</surname><given-names>G.H.</given-names></name><name><surname>Katz</surname><given-names>S.G.</given-names></name><name><surname>Tu</surname><given-names>H.C.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>E.H.</given-names></name><name><surname>Tjandra</surname><given-names>N.</given-names></name><name><surname>Walensky</surname><given-names>L.D.</given-names></name></person-group><year>2008</year><article-title>BAX activation is initiated at a novel interaction site</article-title>.<source>Nature.</source><volume>455</volume>:<fpage>1076</fpage>&#x02013;<lpage>1081</lpage><pub-id pub-id-type="pmid">18948948</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinds</surname><given-names>M.G.</given-names></name><name><surname>Smits</surname><given-names>C.</given-names></name><name><surname>Fredericks-Short</surname><given-names>R.</given-names></name><name><surname>Risk</surname><given-names>J.M.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>D.C.</given-names></name><name><surname>Day</surname><given-names>C.L.</given-names></name></person-group><year>2007</year><article-title>Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets</article-title>.<source>Cell Death Differ.</source><volume>14</volume>:<fpage>128</fpage>&#x02013;<lpage>136</lpage><pub-id pub-id-type="pmid">16645638</pub-id></mixed-citation></ref><ref id="bib2009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabbour</surname><given-names>A.M.</given-names></name><name><surname>Heraud</surname><given-names>J.E.</given-names></name><name><surname>Daunt</surname><given-names>C.P.</given-names></name><name><surname>Kaufmann</surname><given-names>T.</given-names></name><name><surname>Sandow</surname><given-names>J.</given-names></name><name><surname>O'Reilly</surname><given-names>L.A.</given-names></name><name><surname>Callus</surname><given-names>B.A.</given-names></name><name><surname>Lopez</surname><given-names>A.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name><name><surname>Vaux</surname><given-names>D.L.</given-names></name><name><surname>Ekert</surname><given-names>P.G.</given-names></name></person-group><year>2009</year><article-title>Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim</article-title>.<source>Cell Death Differ.</source><volume>16</volume>:<fpage>555</fpage>&#x02013;<lpage>563</lpage><pub-id pub-id-type="pmid">19079139</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Rafiuddin-Shah</surname><given-names>M.</given-names></name><name><surname>Tu</surname><given-names>H.C.</given-names></name><name><surname>Jeffers</surname><given-names>J.R.</given-names></name><name><surname>Zambetti</surname><given-names>G.P.</given-names></name><name><surname>Hsieh</surname><given-names>J.J.</given-names></name><name><surname>Cheng</surname><given-names>E.H.</given-names></name></person-group><year>2006</year><article-title>Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies</article-title>.<source>Nat. Cell Biol.</source><volume>8</volume>:<fpage>1348</fpage>&#x02013;<lpage>1358</lpage><pub-id pub-id-type="pmid">17115033</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwana</surname><given-names>T.</given-names></name><name><surname>Bouchier-Hayes</surname><given-names>L.</given-names></name><name><surname>Chipuk</surname><given-names>J.E.</given-names></name><name><surname>Bonzon</surname><given-names>C.</given-names></name><name><surname>Sullivan</surname><given-names>B.A.</given-names></name><name><surname>Green</surname><given-names>D.R.</given-names></name><name><surname>Newmeyer</surname><given-names>D.D.</given-names></name></person-group><year>2005</year><article-title>BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly</article-title>.<source>Mol. Cell.</source><volume>17</volume>:<fpage>525</fpage>&#x02013;<lpage>535</lpage><pub-id pub-id-type="pmid">15721256</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E.F.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Colman</surname><given-names>P.M.</given-names></name><name><surname>Huang</surname><given-names>D.C.</given-names></name><name><surname>Fairlie</surname><given-names>W.D.</given-names></name></person-group><year>2008</year><article-title>EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency</article-title>.<source>Cell Death Differ.</source><volume>15</volume>:<fpage>1609</fpage>&#x02013;<lpage>1618</lpage><pub-id pub-id-type="pmid">18566606</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemckert</surname><given-names>F.A.</given-names></name><name><surname>Sedgwick</surname><given-names>J.D.</given-names></name><name><surname>Korner</surname><given-names>H.</given-names></name></person-group><year>1997</year><article-title>Gene targeting in C57BL/6 ES cells. Successful germ line transmission using recipient BALB/c blastocysts developmentally matured in vitro</article-title>.<source>Nucleic Acids Res.</source><volume>25</volume>:<fpage>917</fpage>&#x02013;<lpage>918</lpage><pub-id pub-id-type="pmid">9016649</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letai</surname><given-names>A.</given-names></name><name><surname>Bassik</surname><given-names>M.</given-names></name><name><surname>Walensky</surname><given-names>L.</given-names></name><name><surname>Sorcinelli</surname><given-names>M.</given-names></name><name><surname>Weiler</surname><given-names>S.</given-names></name><name><surname>Korsmeyer</surname><given-names>S.</given-names></name></person-group><year>2002</year><article-title>Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics</article-title>.<source>Cancer Cell.</source><volume>2</volume>:<fpage>183</fpage>&#x02013;<lpage>192</lpage><pub-id pub-id-type="pmid">12242151</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovell</surname><given-names>J.F.</given-names></name><name><surname>Billen</surname><given-names>L.P.</given-names></name><name><surname>Bindner</surname><given-names>S.</given-names></name><name><surname>Shamas-Din</surname><given-names>A.</given-names></name><name><surname>Fradin</surname><given-names>C.</given-names></name><name><surname>Leber</surname><given-names>B.</given-names></name><name><surname>Andrews</surname><given-names>D.W.</given-names></name></person-group><year>2008</year><article-title>Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax</article-title>.<source>Cell.</source><volume>135</volume>:<fpage>1074</fpage>&#x02013;<lpage>1084</lpage><pub-id pub-id-type="pmid">19062087</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>K.</given-names></name><name><surname>Nakayama</surname><given-names>K.-I.</given-names></name><name><surname>Negishi</surname><given-names>I.</given-names></name><name><surname>Kuida</surname><given-names>K.</given-names></name><name><surname>Sawa</surname><given-names>H.</given-names></name><name><surname>Loh</surname><given-names>D.Y.</given-names></name></person-group><year>1994</year><article-title>Targeted disruption of bcl-2&#x003b1;&#x003b2; in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>91</volume>:<fpage>3700</fpage>&#x02013;<lpage>3704</lpage><pub-id pub-id-type="pmid">8170972</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connor</surname><given-names>L.</given-names></name><name><surname>Strasser</surname><given-names>A.</given-names></name><name><surname>O'Reilly</surname><given-names>L.A.</given-names></name><name><surname>Hausmann</surname><given-names>G.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Cory</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>D.C.S.</given-names></name></person-group><year>1998</year><article-title>Bim: a novel member of the Bcl-2 family that promotes apoptosis</article-title>.<source>EMBO J.</source><volume>17</volume>:<fpage>384</fpage>&#x02013;<lpage>395</lpage><pub-id pub-id-type="pmid">9430630</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oltersdorf</surname><given-names>T.</given-names></name><name><surname>Elmore</surname><given-names>S.W.</given-names></name><name><surname>Shoemaker</surname><given-names>A.R.</given-names></name><name><surname>Armstrong</surname><given-names>R.C.</given-names></name><name><surname>Augeri</surname><given-names>D.J.</given-names></name><name><surname>Belli</surname><given-names>B.A.</given-names></name><name><surname>Bruncko</surname><given-names>M.</given-names></name><name><surname>Deckwerth</surname><given-names>T.L.</given-names></name><name><surname>Dinges</surname><given-names>J.</given-names></name><name><surname>Hajduk</surname><given-names>P.J.</given-names></name><etal/></person-group><year>2005</year><article-title>An inhibitor of Bcl-2 family proteins induces regression of solid tumours</article-title>.<source>Nature.</source><volume>435</volume>:<fpage>677</fpage>&#x02013;<lpage>681</lpage><pub-id pub-id-type="pmid">15902208</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strasser</surname><given-names>A.</given-names></name></person-group><year>2005</year><article-title>The role of BH3-only proteins in the immune system</article-title>.<source>Nat. Rev. Immunol.</source><volume>5</volume>:<fpage>189</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="pmid">15719025</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walensky</surname><given-names>L.D.</given-names></name><name><surname>Pitter</surname><given-names>K.</given-names></name><name><surname>Morash</surname><given-names>J.</given-names></name><name><surname>Oh</surname><given-names>K.J.</given-names></name><name><surname>Barbuto</surname><given-names>S.</given-names></name><name><surname>Fisher</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>E.</given-names></name><name><surname>Verdine</surname><given-names>G.L.</given-names></name><name><surname>Korsmeyer</surname><given-names>S.J.</given-names></name></person-group><year>2006</year><article-title>A stapled BID BH3 helix directly binds and activates BAX</article-title>.<source>Mol. Cell.</source><volume>24</volume>:<fpage>199</fpage>&#x02013;<lpage>210</lpage><pub-id pub-id-type="pmid">17052454</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>A.</given-names></name><name><surname>Paschen</surname><given-names>S.A.</given-names></name><name><surname>Heger</surname><given-names>K.</given-names></name><name><surname>Wilfling</surname><given-names>F.</given-names></name><name><surname>Frankenberg</surname><given-names>T.</given-names></name><name><surname>Bauerschmitt</surname><given-names>H.</given-names></name><name><surname>Seiffert</surname><given-names>B.M.</given-names></name><name><surname>Kirschnek</surname><given-names>S.</given-names></name><name><surname>Wagner</surname><given-names>H.</given-names></name><name><surname>Hacker</surname><given-names>G.</given-names></name></person-group><year>2007</year><article-title>Bim<sub>S</sub>-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins</article-title>.<source>J. Cell Biol.</source><volume>177</volume>:<fpage>625</fpage>&#x02013;<lpage>636</lpage><pub-id pub-id-type="pmid">17517961</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>S.N.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Dewson</surname><given-names>G.</given-names></name><name><surname>Wei</surname><given-names>A.</given-names></name><name><surname>Naik</surname><given-names>E.</given-names></name><name><surname>Fletcher</surname><given-names>J.I.</given-names></name><name><surname>Adams</surname><given-names>J.M.</given-names></name><name><surname>Huang</surname><given-names>D.C.</given-names></name></person-group><year>2005</year><article-title>Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins</article-title>.<source>Genes Dev.</source><volume>19</volume>:<fpage>1294</fpage>&#x02013;<lpage>1305</lpage><pub-id pub-id-type="pmid">15901672</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willis</surname><given-names>S.N.</given-names></name><name><surname>Fletcher</surname><given-names>J.I.</given-names></name><name><surname>Kaufmann</surname><given-names>T.</given-names></name><name><surname>van Delft</surname><given-names>M.F.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Czabotar</surname><given-names>P.E.</given-names></name><name><surname>Ierino</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>E.F.</given-names></name><name><surname>Fairlie</surname><given-names>W.D.</given-names></name><name><surname>Bouillet</surname><given-names>P.</given-names></name><etal/></person-group><year>2007</year><article-title>Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak</article-title>.<source>Science.</source><volume>315</volume>:<fpage>856</fpage>&#x02013;<lpage>859</lpage><pub-id pub-id-type="pmid">17289999</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Abbreviations used in this paper: MOMP, mitochondrial outer membrane permeabilization; PKD, polycystic kidney disease; tBid, truncated Bid; WBC, white blood cell; WT, wild type.</p></fn></fn-group></back></article>